Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces ‘strong’ progress across its business in the first half of 2023 amid progress for its in-house and partnered programmes. Cash as at June 30 falls 36% to £8.2 million from £12.8 million at December 31. Hails continued roll-out of Ogluo, a glucagon prefilled autoinjector pen used as a treatment for severe hypoglycaemia in children and adults living with diabetes. Glucagon is a hormone that stimulates glucose production in the liver. Arecor expects a second phase I clinical trial on diabetes 2-focused insulin candidate AT278 to complete in the fourth quarter of 2023.
Current stock price: 210.00 pence, up 2.4% on Thursday
12-month change: down 32%
Copyright 2023 Alliance News Ltd. All Rights Reserved.